ANVISA = EMA’s ABEL! [Regulatives / Guidelines]

posted by Lucas – Brazil, 2016-05-19 20:32 (3186 d 22:47 ago) – Posting: # 16336
Views: 11,331

Hi guys.

Earlybird is right. Anvisa is now suggesting the use of EMA's ABEL based on the 2014 WHO guideline. I've discussed with one of ANVISA's statistician and he said that this will probably be included in their own guidelines/resolutions soon. I showed him the thread we had here about TIE inflation but he said they were going to follow the 30% ISCV criteria anyway, because of WHO's guidance, abandoning the >40% "home brewed" criteria. Since it is not yet published as guidelines or resolutions we always submit the protocol for evaluation before initiating the study, even though the answer is always the same. The use of semi or partial replicated designs is also allowed, since blood volume might be a problem for 4-period studies.

Detlew:
As Mauricio said, there isn't a specific guideline determining the ANOVA structure for replicated designs, but I've always used FDA's suggestion (appendix E of 2001 guidance) without problems.

Hope I've been of help.

Lucas Teixeira

Complete thread:

UA Flag
Activity
 Admin contact
23,376 posts in 4,912 threads, 1,666 registered users;
231 visitors (0 registered, 231 guests [including 15 identified bots]).
Forum time: 18:20 CET (Europe/Vienna)

The great tragedy of Science – the slaying
of a beautiful hypothesis by an ugly fact.    Thomas Henry Huxley

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5